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Why early stages in cancer are important? 
 
Oncogene-cell target interaction 
 Clinical malignant tumor mass 
“billion-cell threshold” 
 (Oncology remission means 0 ---- 109 cells) 
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Why is important to know the etiology of cancer? 
Tumour cellular identity (tumour cell fate) 
If cellular fate was immovable, cancer would not be possible, since no new lineages could 
be generated other than the normal, physiological one. 
 
Which is the impact that oncogenes have in establishing the identity of the tumour cell?  
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1- Current model of cancer 
 
2- Tumoral epigenetic stem cell reprogrammimg hypothesis 
 
3- Experimental validation and clinical application 
 
4- Implications in the development and treatment of cancer 
 
 
 
Current model of cancer 
Do the oncogenes have a mode of action that is not homogeneous  
throughout the cancer cell population? 
-Heterogenous tumor cell composition. 
 
-Initiating genetic alteration is present in both CSC and differentiated tumor cells. 
 
-Homogenous mode of action for oncogenes within cancer cells. 
 
-Brief inactivation of oncogenes can cause cancer remission in model systems:oncogene addition 
 
-However, unfortunately, the therapies based on this cancer model fail to eradicate tumours in humans. 
 
Classical model for the role of human cancer gene defects 
in tumour cell fate specification 
Traditionally, the human cancer genetic defects have been thought to act on cells already committed 
 to a differentiation program, in such a way that the tumoural phenotype is derived from that of the initial differentiated target cell 
Assignment of human B-cell 
malignancies to their  
normal B-cell counterparts 
Cobaleda & Sanchez-García, BioEssays, 2009 
Presumptive Celular Origins of Chromosomal translocations  
in Human B-cell malignancies 
Alternative model for the role of human cancer gene 
defects in tumour cell fate specification 
Alternative view in which the oncogenic lesion acts on stem/progenitor cells by imposing  
a given, oncogene-specific, tumour-differentiated cell fate. 

Normal tissue (Blood system) Reprogramming to plutipotency 
We reasoned that a similar organization could be happening for cancer formation 
(hypothesis-driven research project). 
In vivo experimental model of tumoral stem cell 
reprogramming 
To be able to demonstrate this lack of homogeneity in the mode of action of oncogenes throughout the 
biological history of the tumor, it would be necessary to dissect and isolate the function that the oncogene 
is playing at the earliest stages of the disease, at the level of the cell-of-origin 
Human Cancer tissue 
Genetic defect is present in both CSC 
and differentiated tumor cells 
 
In vivo experimental model of 
tumoural stem cell reprogramming 
 
Genetic defect is only present in CSC 
? 
Might cancer stem cells initially arise thorugh a reprogramming-like mechanism? 
 
To be able to demonstrate this lack of homogeneity in the mode of actions of oncogenes throughout the biological history of the tumour. 
This still unexplored possibility would have major implications for our understanding of the genesis and treatment of cancer 
Written on his blackboard at time of his death, in 1988

Sca1 
(a gift of E. Dzierzak) 
How to restrict oncogene expression to the stem cells 
Contribution of CSC to cancer 
biology? 
The key feature of these Sca1 mice is that they express an oncogene under 
 the control of a promoter that is expressed in a population of stem/progenitor cells,  
but is switched off after lineage commitment. 
A cancer without  
Oncogene?? 
Dis Model Mech. 2010 Mar-Apr;3(3-4):149-55 
Oncogene-induced plasticity and CSC 
Stem cell 
compartment CSC proliferating cells 
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compartment Differentiated cells 
Genotype Phenotype 
Translocation 
Genetic 
product 
Tumour type 
t(12;16)(q13;p11) FUS-DDIT3 Myxoid Liposarcoma 
t(16;21)(p11;q22) FUS-ERG Acute myeloid leukaemia 
t(9;22)(q34;q11) BCR-ABLp190 
B acute lymphoblastic 
leukaemia 
t(9;22)(q34;q11) BCR-ABLp210 
Chronic myeloid 
leukaemia 
t(9;22)(q34;q11) BCR-ABLp230 
Chronic neutrophilic 
leukemia  
t( ?;3)( ?;q27) ?+ BCL6 
DLBCL/ Follicular 
lymphoma 
Reprogramming in malignancies originated from stem cells 
In vivo experimental model of tumoural stem cell reprogramming 
EMBO J. 28(1):8-20 (2009). 
Cell Cycle 8:1314-1318 (2009) 
N Engl J Med. 360(3):297-299 (2009) 
1- Proof of principle experiment 
 
2- Chronic myeloid leukemia (CML) stem cells are not oncogene addicted and the therapies 
that biochemically target BCR-ABL do not eliminate them (CML stem cells).  
 
 
3-First animal model aniticipating human clinical results in the CSC field 
 
4-Results were confirmed in human patients two years later 

New concept of the human cancer as a Reprogramming-like Disease  
Can this hypothesis be extrapolated to other malignancies? 
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Other 
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¿? 




Cancer as a result of 
tumoral epigenetic stem cell reprogramming 
 
DNA damage 
 
p53 loss should accelerate the tumor 
reprogramming process 
 
Tumour suppressors can act as barriers for  
tumoural stem cell reprogramming 
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Cell Cycle 2012, 11(20): 3896-3900 (issue cover) 
Are there evidences of tumoral epigenetic stem cell reprogramming?? 
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CSC-specific differentially  
hypomethylated genes 
Identification of a cytosine hypomethylation signature in Sca1-Bcl6  
Genome-scale DNA methylation maps of stem cells and mature B cells 
in mice  predicts human cancer organization 
Whether this mechanism is involved in the genesis of human cancers was presently not known, but recent results confirmed similar cellular hierarchy in human MM patients 

Tumour stem cell reprogramming and therapeutic implications 
Reprogramming the cancer epigenome to an alternative lineage cell fate, non-tumoral fate, losing their malignancy? 
Tumour stem cell reprogramming largely relies on epigenetic modifications. These, unlike genetic changes, can be erased, manipulated, and 
reinitiated, therefore implying that anti-tumour reprogramming strategies can provide a new window of opportunity to interfere with the cancer 
fate-inducing change. 
 
CSCs do not have oncogene addition 
 
 
 
Oncogenes cannot be used as a target to kill CSCs 
 
 
 
BUT, Tumour stem cell reprogramming is a specific CSC 
target 
 
 
 
Could we use it to prevent/kill CSCs? 
Cancer progression also involves CSC evolution 
Evolutionary speciation or ancestral tree, from  
Charles Darwin’s 1837 Transmutation notebook B  
Semin Cancer Biol. 2010 

Genetic background affects susceptibility to tumoral stem cell reprogramming 
 
These results demonstrate for the first time that tumoral stem cell reprogramming fate 
 is subject to polymorphic genetic control  
Genetic background affects stem cell reprogramming in Sca1-BCRABLp210 mice 
 
Strain No. of No. with No.with  No. with  NO TUMORS  
 mice CML(%) B-cell leukemia T-cell lymphoma     
 
B6 23 23(100) 0  0  0   
B6/FVB 35 10(28,5) 6(17,2)  0  19(54,3) 
FVB 11 0 0  11(100)  0  
 
 
 
 
 
 
 
 
 
 
Cell Cycle 2013, 12(15): 2505-2509 (issue cover) 
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